Latest fiscal year 2024 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2024, Petros Pharmaceuticals, Inc. reported revenue of $5M, down 12.2% year over year. Operating margin was -90.5% and net margin -280.1%, on a free-cash-flow margin of -51.4% with capital expenditure at 0.5% of revenue. Every figure is computed directly from PTPI's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2024 | $5M | -90.5% | -280.1% |
| FY2023 | $6M | -233.9% | -140.2% |
| FY2022 | $6M | -332.4% | -334.4% |
| FY2021 | $8M | -231.1% | -115.0% |
| FY2020 | $10M | -180.8% | -215.3% |
How does PTPI compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.